Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial

Y Shen, J Lu, F Hu, J Qian, X Zhang, R Zhong… - Journal of Cancer …, 2023 - Springer
Purpose Liver metastasis (LM) is common in non-small cell lung cancer (NSCLC), and
always predicted worse outcomes with no effective therapy. We aimed to evaluate the effects …
被引用次数：7 相关文章

Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial.

Y Shen, J Lu, F Hu, J Qian, X Zhang… - Journal of Cancer …, 2023 - search.ebscohost.com
Purpose: Liver metastasis (LM) is common in non-small cell lung cancer (NSCLC), and
always predicted worse outcomes with no effective therapy. We aimed to evaluate the effects …

Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial

Y Shen, J Lu, F Hu, J Qian, X Zhang… - Journal of cancer …, 2023 - pubmed.ncbi.nlm.nih.gov
Purpose Liver metastasis (LM) is common in non-small cell lung cancer (NSCLC), and
always predicted worse outcomes with no effective therapy. We aimed to evaluate the effects …

Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial.

Y Shen, J Lu, F Hu, J Qian, X Zhang… - Journal of Cancer …, 2022 - europepmc.org
Purpose Liver metastasis (LM) is common in non-small cell lung cancer (NSCLC), and
always predicted worse outcomes with no effective therapy. We aimed to evaluate the effects …